Low Neural Exosomal Levels of Cellular Survival Factors in Alzheimer's Disease

Edward J. Goetzl  
*University of California - San Francisco*

Adam Boxer  
*University of California - San Francisco*

Janice B. Schwartz  
*University of California - San Francisco*

Erin Abner  
*University of Kentucky, erin.abner@uky.edu*

Ronald C. Petersen  
*Mayo Clinic*

See next page for additional authors

Click here to let us know how access to this document benefits you.

Follow this and additional works at: [https://uknowledge.uky.edu/sbcoa_facpub](https://uknowledge.uky.edu/sbcoa_facpub)

Part of the [Family, Life Course, and Society Commons](https://uknowledge.uky.edu/family_lifecycle/), and the [Geriatrics Commons](https://uknowledge.uky.edu/geriatrics)

Repository Citation
Goetzl, Edward J.; Boxer, Adam; Schwartz, Janice B.; Abner, Erin; Petersen, Ronald C.; Miller, Bruce L.; Carlson, Olga D.; Mustapic, Maja; and Kapogiannis, Dimitrios, "Low Neural Exosomal Levels of Cellular Survival Factors in Alzheimer’s Disease" (2015). Sanders-Brown Center on Aging Faculty Publications. 60. 
[https://uknowledge.uky.edu/sbcoa_facpub/60](https://uknowledge.uky.edu/sbcoa_facpub/60)

This Article is brought to you for free and open access by the Aging at UKnowledge. It has been accepted for inclusion in Sanders-Brown Center on Aging Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Authors
Edward J. Goetzl, Adam Boxer, Janice B. Schwartz, Erin Abner, Ronald C. Petersen, Bruce L. Miller, Olga D. Carlson, Maja Mustapic, and Dimitrios Kapogiannis

Low Neural Exosomal Levels of Cellular Survival Factors in Alzheimer's Disease

Notes/Citation Information


This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Digital Object Identifier (DOI)
http://dx.doi.org/10.1002/acn3.211

This article is available at UKnowledge: https://uknowledge.uky.edu/sbcoa_facpub/60
Low neural exosomal levels of cellular survival factors in Alzheimer’s disease
Edward J. Goetzl, Adam Boxer, Janice B. Schwartz, Erin L. Abner, Ronald C. Petersen, Bruce L. Miller, Olga D. Carlson, Maja Mustapic & Dimitrios Kapogiannis

1 Department of Medicine, UCSF Medical Center and the Jewish Home of San Francisco, San Francisco, California
2 Memory and Aging Center, Department of Neurology, UCSF Medical Center, San Francisco, California
3 Departments of Medicine and Bioengineering, UCSF Medical Center and the Jewish Home of San Francisco, San Francisco, California
4 Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky
5 Department of Neurology, Mayo Clinic, Rochester, Minnesota
6 Intramural Research Program, National Institute on Aging, Baltimore, Maryland

Correspondence
Edward J. Goetzl, 1719 Broderick St., San Francisco, CA 94115. Tel: 703-254-7529; Fax: 415-400-5471; E-mail: edward.goetzl@ucsf.edu
or Dimitrios Kapogiannis, E-mail: kapogiannisd@mail.nih.gov

Funding Information
Intramural Research Program of the National Institute on Aging (D. K.), P30 AG028383 (E. L. A.), and an unrestricted grant for method development from Nanosomix, Inc. (E. J. G.).

Received: 19 January 2015; Revised: 8 April 2015; Accepted: 11 April 2015

Abstract
Transcription factors that mediate neuronal defenses against diverse stresses were quantified in plasma neural-derived exosomes of Alzheimer’s disease or frontotemporal dementia patients and matched controls. Exosomal levels of low-density lipoprotein receptor-related protein 6, heat-shock factor-1, and repressor element 1-silencing transcription factor all were significantly lower in Alzheimer’s disease patients than controls (P < 0.0001). In frontotemporal dementia, the only significant difference was higher levels of repressor element 1-silencing transcription factor than in controls. Exosomal transcription factors were diminished 2–10 years before clinical diagnosis of Alzheimer’s disease. Low exosomal levels of survival proteins may explain decreased neuronal resistance to Alzheimer’s disease neurotoxic proteins.

Introduction
Deficiencies of transcription factors that protect neurons from diverse stresses have been implicated in progression and severity of Alzheimer’s disease (AD).1,2 Repressor element 1-silencing transcription factor (REST) is expressed at high levels in aging human brain, where it maintains factors that enhance neuronal resistance to stresses and apoptosis.1,3 Nuclear levels of REST and its recognition motif, termed RE1, are lower in autopsy brain tissues of patients with AD than cognitively normal controls.1 A complex of low-density lipoprotein receptor-related protein 6 (LRP6) and Frizzled receptors bind Wnt ligands and thereby evoke nuclear translocation of β-catenin that activates genes encoding survival factors such as REST.4–6 As for REST, LRP6-Wnt signaling is decreased in autopsy brain tissue from AD patients and deletion of the Lrp6 gene selectively in mouse forebrain neurons enhances AD-like pathology.2 The heat-shock factor-1 (HSF1) maintains neuronal defenses by increasing expression of heat-shock family chaperones and cytoskeletal-protective calcium-sensing proteins, but has not been adequately studied in human neurodegenerative diseases.7–9 Recent analyses of proteins extracted from immunochemically isolated neurally derived plasma exosomes have shown significantly higher levels of pathogenic P-T181-tau, P-S396-tau and Aβ1–42, as well as altered levels of phosphorylated forms of the insulin receptor proximal signaling protein, termed insulin receptor substrate (IRS) in AD as contrasted with controls.10,11 Plasma neurally derived exosomal levels of P-T181-tau, P-S396-tau, Aβ1–42, and phosphorylated forms of IRS were significantly
Defective Neural Survival in Alzheimer’s Disease

E. J. Goetzl et al.

Patients and Methods

Experimental design and patient evaluation

We identified 24 patients for cross-sectional studies (one blood sample at the National Institute on Aging [NIA]) and 16 patients for longitudinal studies (one blood sample at diagnosis [longitudinal AD set] and another 2–10 years earlier [longitudinal AP set] at the Mayo Clinic or the University of Kentucky) (Table 1). Samples from the longitudinal study were analyzed without knowledge of any clinical data. Amnestic mild cognitive impairment (MCI) and dementia from AD were diagnosed as described, using established criteria.10,11 Ten patients with the behavioral variant of frontotemporal dementia (FTD) were from the Memory and Aging Center of the Department of Neurology of the University of California, San Francisco. Their diagnosis and assignment to mild or moderate dementia groups (Table 1) were based on standard criteria.10-17 Cognitively normal control subjects for FTD (FTC) and both AD sets (AC) were from the NIA (28/50) or the Jewish Home of San Francisco (22/50) and were matched by age, gender, and race to FTD and AD patients in cross-sectional and longitudinal studies.

Table 1. Characteristics of patients and control subjects.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Total</th>
<th>Neurological Subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Male/female</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(A) Cross-sectional studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AD</td>
<td>24</td>
<td>12/12</td>
</tr>
<tr>
<td>AC</td>
<td>24</td>
<td>12/12</td>
</tr>
<tr>
<td>FTD</td>
<td>10</td>
<td>7/3</td>
</tr>
<tr>
<td>FTC</td>
<td>10</td>
<td>7/3</td>
</tr>
<tr>
<td>(B) Longitudinal studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP</td>
<td>16</td>
<td>7/9</td>
</tr>
<tr>
<td>AD</td>
<td>16</td>
<td>7/9</td>
</tr>
<tr>
<td>AC</td>
<td>16</td>
<td>7/9</td>
</tr>
</tbody>
</table>

The significance of differences in MMSE values between AD dementia and MCI (parts A and B), and between FTD moderate dementia and mild dementia (part A) were calculated by an unpaired t test. MMSE, Mini-Mental State Examination; n, number of subjects; AD, Alzheimer’s disease; MCI, mild cognitive impairment; FTD, frontotemporal dementia.

*P < 0.01 and **P < 0.001.

Each subject and some patient designates signed consent forms approved with the protocol at each institution. Thirty milliliter of venous blood were drawn into 100 U/mL of heparin and centrifuged for 15 min at 2000g. Plasmas were stored in 0.5 mL aliquots at −80°C.

Isolation of plasma exosomes for extraction and Enzyme-Linked Immunosorbent Assay (ELISA) quantification of exosome proteins

Two hundred fifty microliters of plasma were incubated with 0.10 mL of thromboplastin-D (Fisher Scientific, Inc., Hanover Park, IL) followed by addition of 0.15 mL of calcium- and magnesium-free Dulbecco’s balanced salt solution (DBS°−) with three-times the recommended concentrations of protease inhibitor cocktail (Roche Applied Sciences, Inc., Indianapolis, IN) and phosphatase inhibitor cocktail (Pierce Halt; Thermo Scientific, Inc., Rockford, IL).10,11 ExoQuick (EXOQ; System Biosciences, Inc., Mountainview, CA) was added to 3000g supernates to precipitate total exosomes, that were re-suspended for immunochemical enrichment of exosomes from neural sources.10,11

Exosomes absorbed by mouse anti-human CD171 (L1 cell adhesion molecule [L1CAM] neural adhesion protein) biotinylated antibody (clone 5G3; eBioscience, San Diego, CA) and Streptavidin-Plus UltraLink resin (Pierce-Thermo Scientific, Inc.) were released into 50 μL of 0.05 mol/L Tris acetic acid (pH 2.5) followed by addition to 3000g supernates of 42 μL of 3% bovine serum albumin (BSA), 8 μL of 1 mol/L Tris-HCl (pH 8.0) and...
0.40 mL of M-PER mammalian protein extraction reagent (Thermo Scientific, Inc.).10,11

Neural exosomal proteins neuron-specific enolase (NS-enolase) (R&D Systems, Inc., Minneapolis, MN), type 1 neural cell adhesion molecule (NCAM-1) (Raybiotech, Inc., Norcross, GA) and tetraspanning exosome marker human CD81 (Cusabio-American Research Products, Inc., Waltham, MA) were quantified in the linear range of ELISAs. Transcription factors were quantified by ELISAs for HSF1 (Enzo Life Sciences, Inc., Farmingdale, NY), REST (Cusabio, American Research Products, Inc.), and LRP6 (USCN Life Science, Inc., American Research Products, Inc.). Neural exosomal levels of CD81 (mean ± SEM, n = 40) were 5.98 ± 0.76 ng/mL for AD patients and 5.44 ± 0.82 ng/mL for AC controls, indicating the same total amount of exosomes.

The mean value for all determinations of CD81 in each assay group was set at 1.00 and the relative values for each sample used to normalize their exosomal content. A neural origin and enrichment of neural exosomes by anti-L1CAM antibody absorption were supported by enhanced content of NCAM-1 and NS-enolase (Table S1).20

Statistical analyses

The statistical significance of differences between means for each patient group and their respective control group was determined with an unpaired t test including a Bonferroni correction (GraphPad Prism 6, La Jolla, CA). For longitudinal analyses, the significance of differences between AP and AD values was calculated with a paired t test (GraphPad). Discriminant classification modeling and receiver operating characteristic (ROC) analyses of proteins in the AD versus AC cross-sectional groups were conducted as described.10,11

Results

Transcription factor levels of plasma neural exosomes were significantly lower for AD patients than AC control subjects in the cross-sectional study (Fig. 1). The mean ± SEM levels of LRP6, HSF1, and REST for AD patients (483 ± 49.9, 102 ± 3.96, and 47.4 ± 8.16 pg/mL, respectively) were significantly lower than those for AC controls (1028 ± 64.7, 319 ± 32.0, and 667 ± 140 pg/mL) (all P < 0.0001). In contrast, there were no significant differences in LRP6 or HSF1 between the FTD (857 ± 96.2 and 274 ± 51.0 pg/mL, respectively) and FTC (1104 ± 94 and 341 ± 51.4 pg/mL) groups (Fig. 1). The REST level was significantly higher for FTD patients (2065 ± 162 pg/mL) than FTC controls (691 ± 123 pg/mL) (P < 0.0001), in contrast to earlier findings of lower values in brain tissues.1 There were no differences between levels of the transcription factors in AD patients with MCI and those with dementia (Table S2). ROC analyses of all analytes correctly classified 79% of AC subjects and 92% of AD patients (Fig. S1), as had primary pathogenic proteins.10

The results of longitudinal studies were confirmatory, as each of the plasma neural-derived exosomal protein levels for AD patients 2–10 years before (AP group) and at the time of diagnosis (AD group) were significantly lower than for AC control subjects (Fig. 2). The mean ± SEM levels of LRP6, HSF1, and REST for the AD group (568 ± 26.3, 140 ± 9.75, and 13.8 ± 1.87 pg/mL, respectively) and for the AP group (689 ± 23.6, 183 ± 9.95, and 30.7 ± 5.37 pg/mL) were significantly lower than those for AC controls (1028 ± 64.7, 319 ± 32.0, and 667 ± 140 pg/mL) (all P < 0.0001). The respective levels for the AD group all were significantly lower than those for the AP group (P values of 0.0019, 0.0034, and 0.0066). Thus, levels of these transcription factors were significantly low years before appearance of clinical signs of AD and there was continued declination with time. There were no differences between levels of any of the transcription factors in AP samples obtained 2–5 years before and 6–10 years before diagnosis.

Discussion

It is difficult to assign distinct contributions to each of the pathogenic mechanisms and deficient neuronal survival in AD, as has been indicated by the pathological and functional changes that underlie the neurodegenerative process. The results of this study suggest a decrease in levels of neural exosomal proteins years before the appearance of clinical signs of AD, which may be indicative of a pathological change that precedes the clinical diagnosis. The significant differences in transcription factor levels between AD and AC, as well as between FTD and FTC, suggest that the decrease in levels of neural exosomal proteins is a specific marker of AD and FTD, respectively. This finding is consistent with previous studies that have reported lower levels of these proteins in brain tissues of AD and FTD patients, indicating a potential role for these proteins in the pathogenesis of these disorders.

Figure 1. Levels of neural-derived plasma exosomal proteins in patients with Alzheimer’s disease (AD), frontotemporal dementia (FTD), and matched cognitively normal case controls (AC, FTC). The horizontal line in each cluster here and in Figure 2 depicts the mean for that set.
defenses involved in AD. However, the low neural exosomal levels of critical survival factors in AD reported here (Figs. 1, 2) are of a degree similar to that of the increases in neural exosomal pathogenic proteins\textsuperscript{10,11} and suggest a loss of resistance to neurotoxic proteins that is likely to increase susceptibility to development of AD. It also is possible to conclude that the extent of deficiency of these survival factors detected in neural plasma exosomes is similar to those found in human brain tissues from patients with AD at autopsy and analogous to those in mouse models with targeted deletions that result in earlier and more severe AD-like disease.\textsuperscript{1,2} 

The Wnt signaling pathway regulates neurogenesis and diverse neurodevelopmental processes, as well as a variety of synaptic functions.\textsuperscript{4} Of the transcriptional factors here found to be deficient in AD, LRP6 is a mediator of Wnt signaling and REST is a Wnt signal target.\textsuperscript{1,2,5,6} Thus, a deficiency in LRP6 which diminishes Wnt signaling may contribute to reduced nuclear localization and activation of REST.

Major survival factor deficiencies 2–10 years before appearance of diagnostic clinical signs of AD (Fig. 2) suggest a possible early pathogenic contribution of increased neuronal susceptibility to neurotoxic proteins in AD beyond higher levels of the pathogenic proteins.\textsuperscript{10,11} Validation of this platform will require larger studies analyzing profiles of these factors for individual patients and correlating results with those of cerebral bioimaging and pathology.

Acknowledgments
The authors are grateful to Lynn Kane (JHSF), Anna Karydas (UCSF MAC), Dana Swenson-Dravis and Matthew Miller (Mayo Clinic), Sonya Anderson (University of Kentucky), and Melissa Swaby (NIA) for organizing and distributing clinical materials and data. We thank Judith H. Goetzl for expert preparation of graphic illustrations.

Author Contributions
E. J. G. developed analytical methodology, performed laboratory benchwork, analyzed data, wrote, and edited manuscript. A. B. evaluated patients, analyzed data, edited manuscript. J. B. S. analyzed data, wrote, and edited manuscript. E. L. A. evaluated patients, analyzed data, edited manuscript. R. C. P. evaluated patients, analyzed data, edited manuscript. B. L. M. evaluated patients, analyzed data, edited manuscript. O. D. C. analyzed data, edited manuscript. M. M. performed laboratory benchwork, analyzed data, edited manuscript. D. K. evaluated patients, analyzed data, performed statistical analyses, edited manuscript.

Conflict of Interest
Three authors report possible conflicts of interest. Dr. Petersen is chair of the Data Monitoring Committee Pfizer, Inc. and Janssen Alzheimer Immunotherapy, and a consultant for Merck, Inc., Roche, Inc. and Genentech, Inc. Dr. Boxer declares that outside the submitted studies he has grants from NIH/NIA, grants from Tau Research Consortium, grants from Corticobasal Degeneration Solutions, grants, personal fees and nonfinancial support from Archer Biosciences, grants from Allon Therapeutics, personal fees from Acetylon, personal fees from Ipierian, grants from Genentech, grants from Bristol Myers Squibb, grants from TauRx, grants from Alzheimer’s Association, grants from Bluefield Project to Cure FTD, grants from Association for Frontotemporal Degeneration, grants from Alzheimer’s Drug Discovery Foundation, grants from EnVivo, grants from C2N Diagnostics, grants from Pfizer, and grants from Eli Lilly. Dr. Goetzl has filed a provisional application with the U.S. Patent Office for the platform and methodologies described in this report.

References


Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. ROC plots depicting distinctions between AD and AC. Discriminant classifier analysis attained a Wilk’s Lambda of 0.395 and an exact F of 34.417 (P < 0.0001), and correctly classified 79% of AC subjects and 92% of AD patients. Of the proteins assessed, all had asymptotic significance <0.001 and achieved excellent classification in a rank order of REST (area under the curve [AUC] 0.944), HSF1 (AUC 0.944), and LRP6 (AUC 0.924).

Table S1. Immunochemical enrichment of neuronal markers in plasma exosomes. Each pg/mL value is the mean ± SEM of determinations for five plasma samples from AD patients or matched AC controls after normali-

Table S2. Levels of serum exosome proteins in relation to severity of dementia in AD. All values are mean ± SEM, pg/mL. None of the differences between values for the MCI and dementia groups was significant.